awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q58801701-9470206E-1DB9-4734-8E49-EDAB48E36A8A
Q58801701-9470206E-1DB9-4734-8E49-EDAB48E36A8A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58801701-9470206E-1DB9-4734-8E49-EDAB48E36A8A
New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective
P2860
Q58801701-9470206E-1DB9-4734-8E49-EDAB48E36A8A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58801701-9470206E-1DB9-4734-8E49-EDAB48E36A8A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8ee31626b40c63e3c17836c4f9529567db505239
P2860
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days